Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.

Ultsch, Bernhard; Weidemann, Felix; Reinhold, Thomas; Siedler, Anette; Krause, Gerard; Wichmann, Ole

dc.contributor.author	Ultsch, Bernhard
dc.contributor.author	Weidemann, Felix
dc.contributor.author	Reinhold, Thomas
dc.contributor.author	Siedler, Anette
dc.contributor.author	Krause, Gerard
dc.contributor.author	Wichmann, Ole
dc.date.accessioned	2015-11-25T15:53:39Z	en
dc.date.available	2015-11-25T15:53:39Z	en
dc.date.issued	2013	en
dc.identifier.citation	Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany. 2013, 13:359 BMC Health Serv Res	en
dc.identifier.issn	1472-6963	en
dc.identifier.pmid	24070414	en
dc.identifier.doi	10.1186/1472-6963-13-359	en
dc.identifier.uri	http://hdl.handle.net/10033/582736	en
dc.description.abstract	Herpes zoster (HZ) is a self-limiting painful skin rash affecting mostly individuals from 50 years of age. The main complication is postherpetic neuralgia (PHN), a long-lasting pain after rash has resolved. A HZ-vaccine has recently been licensed in Europe for individuals older than 50 years. To support an informed decision-making for a potential vaccination recommendation, we conducted a health economic evaluation to identify the most cost-effective vaccination strategy.
dc.language.iso	en	en
dc.subject.mesh	Aged	en
dc.subject.mesh	Aged, 80 and over	en
dc.subject.mesh	Cost-Benefit Analysis	en
dc.subject.mesh	Female	en
dc.subject.mesh	Germany	en
dc.subject.mesh	Health Care Costs	en
dc.subject.mesh	Herpes Zoster	en
dc.subject.mesh	Herpes Zoster Vaccine	en
dc.subject.mesh	Humans	en
dc.subject.mesh	Male	en
dc.subject.mesh	Markov Chains	en
dc.subject.mesh	Middle Aged	en
dc.subject.mesh	Models, Economic	en
dc.subject.mesh	Neuralgia, Postherpetic	en
dc.subject.mesh	Quality-Adjusted Life Years	en
dc.title	Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.	en
dc.type	Article	en
dc.contributor.department	Helmholtz Centre for infection research, Inhoffenstr. 7, D-38124 Braunschweig, Germany.	en
dc.identifier.journal	BMC health services research	en
refterms.dateFOA	2018-06-13T09:19:42Z
html.description.abstract	Herpes zoster (HZ) is a self-limiting painful skin rash affecting mostly individuals from 50 years of age. The main complication is postherpetic neuralgia (PHN), a long-lasting pain after rash has resolved. A HZ-vaccine has recently been licensed in Europe for individuals older than 50 years. To support an informed decision-making for a potential vaccination recommendation, we conducted a health economic evaluation to identify the most cost-effective vaccination strategy.